Your browser doesn't support javascript.
loading
CaMuS: simultaneous fitting and de novo imputation of cancer mutational signature.
Cartolano, Maria; Abedpour, Nima; Achter, Viktor; Yang, Tsun-Po; Ackermann, Sandra; Fischer, Matthias; Peifer, Martin.
Afiliação
  • Cartolano M; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.
  • Abedpour N; Center for Molecular Medicine Cologne, Medical Faculty, University Hospital Cologne, Cologne, Germany.
  • Achter V; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.
  • Yang TP; Center for Molecular Medicine Cologne, Medical Faculty, University Hospital Cologne, Cologne, Germany.
  • Ackermann S; Computing Center, University of Cologne, Cologne, Germany.
  • Fischer M; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.
  • Peifer M; Center for Molecular Medicine Cologne, Medical Faculty, University Hospital Cologne, Cologne, Germany.
Sci Rep ; 10(1): 19316, 2020 11 09.
Article em En | MEDLINE | ID: mdl-33168834
The identification of the mutational processes operating in tumour cells has implications for cancer diagnosis and therapy. These processes leave mutational patterns on the cancer genomes, which are referred to as mutational signatures. Recently, 81 mutational signatures have been inferred using computational algorithms on sequencing data of 23,879 samples. However, these published signatures may not always offer a comprehensive view on the biological processes underlying tumour types that are not included or underrepresented in the reference studies. To circumvent this problem, we designed CaMuS (Cancer Mutational Signatures) to construct de novo signatures while simultaneously fitting publicly available mutational signatures. Furthermore, we propose to estimate signature similarity by comparing probability distributions using the Hellinger distance. We applied CaMuS to infer signatures of mutational processes in poorly studied cancer types. We used whole genome sequencing data of 56 neuroblastoma, thus providing evidence for the versatility of CaMuS. Using simulated data, we compared the performance of CaMuS to sigfit, a recently developed algorithm with comparable inference functionalities. CaMuS and sigfit reconstructed the simulated datasets with similar accuracy; however two main features may argue for CaMuS over sigfit: (i) superior computational performance and (ii) a reliable parameter selection method to avoid spurious signatures.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Software / Neoplasias Encefálicas / Análise Mutacional de DNA / Biologia Computacional / Neuroblastoma Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Software / Neoplasias Encefálicas / Análise Mutacional de DNA / Biologia Computacional / Neuroblastoma Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article